Minimally invasive spine therapy company SpineOvations reported favorable results at the midpoint of its DiscSeal clinical trial.
DiscSeal is a viscous material injected percutaneously into the intervertebral diseased disc of patients under local anesthesia.
Beginning in February, the study is examining the safety and efficacy of DiscSeal in patients suffering from lumbar pain.
Results at the 90-day midpoint indicate a reduction in lumbar pain, leg pain and disability.
Led by James Yu, MD, the trial is examining the treatment in six patients with lumbar pain caused by discogenic disease who have not responded to first-line medical therapy.
SpineOvations will report final study findings in late summer.
Click here to view 90-day interim results from the study.